Capricor Therapeutics Stock Analysis

Capricor Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The book value of Capricor Therapeutics was currently reported as 1.69. The company recorded a loss per share of 1.15. Capricor Therapeutics last dividend was issued on the 5th of June 2019. The entity had 1:10 split on the 5th of June 2019. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. The company was founded in 2005 and is headquartered in San Diego, California. Capricor Therap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people. For more info on Capricor Therapeutics please contact the company at 858 727 1755 or go to https://www.capricor.com.

Capricor Therapeutics Investment Alerts

Capricor Therapeutics Upcoming and Recent Events

Capricor Largest EPS Surprises

View All Earnings Estimates

Capricor Therapeutics Environmental, Social, and Governance (ESG) Scores

Capricor Stock Institutional Investors

Note, although Capricor Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Capricor Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 605.33 M.

Capricor Profitablity

The company has Profit Margin (PM) of (1.82) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.69) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.69.

Management Efficiency

Capricor Therapeutics has return on total asset (ROA) of (0.3473) % which means that it has lost $0.3473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8907) %, meaning that it created substantial loss on money invested by shareholders. Capricor Therapeutics' management efficiency ratios could be used to measure how well Capricor Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/25/2025, Return On Tangible Assets is likely to drop to -0.36. In addition to that, Return On Capital Employed is likely to grow to -0.96. At this time, Capricor Therapeutics' Total Assets are relatively stable compared to the past year. As of 03/25/2025, Total Current Assets is likely to grow to about 89.3 M, though Non Currrent Assets Other are likely to grow to (80.8 M).

Technical Drivers

As of the 25th of March, Capricor Therapeutics shows the Mean Deviation of 3.91, downside deviation of 5.01, and Risk Adjusted Performance of 0.0199. Capricor Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Capricor Therapeutics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Capricor Therapeutics is priced correctly, providing market reflects its regular price of 13.5 per share. Given that Capricor Therapeutics has jensen alpha of 0.1135, we suggest you to validate Capricor Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Capricor Therapeutics Price Movement Analysis

Capricor Therapeutics Insider Trading Activities

Capricor Therapeutics Outstanding Bonds

Capricor Therapeutics Predictive Daily Indicators

Capricor Therapeutics Corporate Filings

Capricor Therapeutics Forecast Models

Capricor Therapeutics' time-series forecasting models are one of many Capricor Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Capricor Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Capricor Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Capricor shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Capricor Therapeutics. By using and applying Capricor Stock analysis, traders can create a robust methodology for identifying Capricor entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Capricor analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Capricor analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Capricor Therapeutics stock analysis indicators help investors evaluate how Capricor Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Capricor Therapeutics shares will generate the highest return on investment. By understating and applying Capricor Therapeutics stock analysis, traders can identify Capricor Therapeutics position entry and exit signals to maximize returns.

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.